Compile Data Set for Download or QSAR
Report error Found 36 Enz. Inhib. hit(s) with all data for entry = 12470
TargetNon-receptor tyrosine-protein kinase TYK2 [556-888](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704700(US20240376080, Compound 4R)
Affinity DataIC50: 0.100nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [556-888](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704696(US20240376080, Compound 1R)
Affinity DataIC50: 0.100nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [556-888](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704699(US20240376080, Compound 4S)
Affinity DataIC50: 0.120nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [556-888](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704697(US20240376080, Compound 2S)
Affinity DataIC50: 0.130nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [556-888](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704695(US20240376080, Compound 1S)
Affinity DataIC50: 0.130nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [556-888](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704698(US20240376080, Compound 2R)
Affinity DataIC50: 0.200nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [583-855](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704697(US20240376080, Compound 2S)
Affinity DataIC50: 0.670nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [583-855](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704695(US20240376080, Compound 1S)
Affinity DataIC50: 0.700nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [583-855](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704696(US20240376080, Compound 1R)
Affinity DataIC50: 0.900nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [583-855](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704699(US20240376080, Compound 4S)
Affinity DataIC50: 1.66nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [583-855](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704698(US20240376080, Compound 2R)
Affinity DataIC50: 1.70nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [583-855](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704700(US20240376080, Compound 4R)
Affinity DataIC50: 3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [861-1152](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704698(US20240376080, Compound 2R)
Affinity DataIC50: 698nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [861-1152](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704696(US20240376080, Compound 1R)
Affinity DataIC50: 1.41E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [861-1152](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704697(US20240376080, Compound 2S)
Affinity DataIC50: 1.47E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [831-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704697(US20240376080, Compound 2S)
Affinity DataIC50: 2.19E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [811-1124](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704698(US20240376080, Compound 2R)
Affinity DataIC50: 3.68E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [861-1152](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704700(US20240376080, Compound 4R)
Affinity DataIC50: 5.37E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [811-1124](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704697(US20240376080, Compound 2S)
Affinity DataIC50: 5.40E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [811-1124](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704695(US20240376080, Compound 1S)
Affinity DataIC50: 8.67E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [831-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704700(US20240376080, Compound 4R)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [811-1124](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704699(US20240376080, Compound 4S)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [811-1124](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704700(US20240376080, Compound 4R)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704700(US20240376080, Compound 4R)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704695(US20240376080, Compound 1S)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [831-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704699(US20240376080, Compound 4S)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [861-1152](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704699(US20240376080, Compound 4S)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704699(US20240376080, Compound 4S)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [831-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704698(US20240376080, Compound 2R)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704698(US20240376080, Compound 2R)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704697(US20240376080, Compound 2S)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [811-1124](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704696(US20240376080, Compound 1R)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [831-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704696(US20240376080, Compound 1R)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704696(US20240376080, Compound 1R)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [831-1132](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704695(US20240376080, Compound 1S)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [861-1152](Human)
Zhejiang Wenda Pharmaceutical Technology

US Patent
LigandPNGBDBM704695(US20240376080, Compound 1S)
Affinity DataIC50: 9.95E+3nMAssay Description:1. Experimental Method1.1. Pseudokinase (JH2) Experimental Operation was as Follows:1.1.1. Dissolve the compound with DMSO to a storage concentration...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
Go to US Patent